Amsterdam, Netherlands – April 22, 2026

In a significant advancement for medical imaging technology, Philips has received U.S. FDA 510(k) clearance for its Rembra platform, including Rembra CT, Rembra RT, and Areta RT systems, marking a major step forward in high-throughput, precision-driven CT imaging and radiation therapy planning. This milestone reinforces Philips’ commitment to delivering faster, scalable, and more accurate imaging solutions to address growing clinical demand and complexity across healthcare systems worldwide.

Next-Generation CT Platform Enhancing Speed and Access

The newly cleared Rembra platform is designed to meet the increasing need for rapid, high-volume imaging in frontline care settings, enabling healthcare providers to manage rising patient loads without compromising diagnostic accuracy. The flagship Rembra CT system features an industry-leading 85 cm bore, allowing for enhanced patient access and flexibility across emergency departments, intensive care units, and interventional environments.

With the ability to support up to 270 exams per day, the platform delivers ultra-fast image acquisition and advanced reconstruction capabilities, ensuring clinicians can make timely, informed decisions in critical care scenarios. These features are particularly valuable in acute settings where speed and precision are essential for improving patient outcomes.

The integration of intelligent workflows and scalable imaging capabilities further enables healthcare providers to streamline operations, reduce bottlenecks, and maintain consistent image quality across high-demand environments.

Advertisement

cGxPJobs Banner

Advancing Precision in Cancer Treatment Planning

Beyond diagnostic imaging, the Rembra platform extends its capabilities into radiation oncology, with Rembra RT and Areta RT systems specifically designed for high-precision treatment planning. These systems incorporate next-generation 4D CT imaging technology, enabling clinicians to capture dynamic tumor motion and improve targeting accuracy during radiation therapy.

The platform’s extended 85 cm field of view supports comprehensive imaging for treatment simulation, allowing for more accurate delineation of tumors while minimizing exposure to healthy tissues. This is critical in oncology care, where precision directly impacts treatment efficacy and patient safety.

By enhancing workflow efficiency and reducing variability in treatment planning, the Rembra platform supports a more personalized and consistent approach to cancer care, aligning with the broader shift toward precision medicine in oncology.

Integrated Imaging Ecosystem Transforming Care Delivery

The Rembra platform represents a unified CT ecosystem that bridges diagnostic radiology and therapeutic planning, enabling a connected care pathway from initial diagnosis to targeted treatment. This integration allows healthcare providers to deliver coordinated, data-driven care, improving both clinical efficiency and patient experience.

As healthcare systems face increasing pressure from rising imaging volumes and complex clinical cases, solutions like Rembra provide the scalability and performance needed to maintain high standards of care. The platform’s ability to combine speed, precision, and connectivity positions it as a critical tool in modern healthcare environments.

Philips’ latest FDA clearance also strengthens its comprehensive CT portfolio, reflecting ongoing innovation in advanced imaging technologies and intelligent workflow integration. By aligning diagnostic and therapeutic capabilities within a single platform, Philips aims to enhance clinical confidence, improve operational efficiency, and expand access to high-quality imaging services globally.

This development underscores a broader trend in healthcare toward integrated, technology-driven solutions that support faster diagnosis, more precise treatments, and improved patient outcomes, solidifying Philips’ role as a leader in next-generation medical imaging innovation.

Source: Philips press release